GlassScriptPhysician profile
Antonio Ds Lopez
NPI 1063492536
$3,383.56
in general payments reported to CMS, 2019-2025
28 companies · $30.69 in 2025
The $30.69 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $300 · 2021: $982 · 2022: $1,008 · 2023: $22.58 · 2025: $30.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.06 | 2021-2022 | |
| Novo Nordisk INC | $369.65 | 2019-2022 | |
| Lilly USA, LLC | $360.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $318.53 | 2019-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.58 | 2019-2022 | |
| Amgen INC. | $170.07 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.74 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $111.40 | 2020-2022 | |
| Pfizer INC. | $104.03 | 2019-2020 | |
| Optinose US, INC. | $87.94 | 2019-2021 | |
| Astellas Pharma US INC | $87.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $86.54 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.03 | 2019-2022 | |
| Genentech USA, INC. | $53.90 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $52.05 | 2022 | |
| Shire North American Group INC | $33.46 | 2019 | |
| Tonix Medicines, INC. | $30.69 | 2025 | Tonmya |
| Amarin Pharma, INC. | $29.41 | 2019 | |
| Vistapharm, INC. | $28.84 | 2021 | |
| Scilex Pharmaceuticals INC. | $21.86 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.47 | 2022 | |
| Redhill Biopharma INC. | $18.74 | 2021 | |
| Horizon Therapeutics Plc | $15.36 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.71 | 2020 | |
| Mdd US Operations, LLC | $13.61 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.13 | 2020 | |
| Allergan, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.